MASH Pharmacotherapy Network Meta-Analysis Results Table

A network meta-analysis of 34 Phase II/III randomized controlled trials comparing pharmacological agents for metabolic dysfunction-associated steatohepatitis (MASH). The dataset, authored by Mengshi Tang and last updated in June 2026, includes relative risk estimates for outcomes like fibrosis improvement and MASH resolution across drug classes including FGF21 analogs, SGLT2 inhibitors, GLP-1 RAs, and THR-β agonists.

Use Cases

• Compare the efficacy of different drug classes for MASH based on relative risk estimates for fibrosis improvement.
• Assess the benefit-risk profiles of therapies using the two-dimensional cluster analysis results mentioned in the description.
• Validate the robustness of drug rankings for MASH resolution through sensitivity analyses excluding small-scale studies.

Strengths

• Includes results from 34 studies across 33 unique publications, providing a broad evidence base.
• Reports specific relative risk values and confidence intervals (e.g., RR 2.27, 95% CI 1.22-4.17 for SGLT2 inhibitors).
• Systematic review is registered with PROSPERO (CRD420261292638), indicating a structured methodology.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of published Phase II/III randomized controlled trials.

Freshness

Last updated 2026-06-04 04:30:33; freshness should be verified.